Arakis and Vectura in COPD Alliance with Novartis
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 59 (Table of Contents)
Published: 5 May-2005
DOI: 10.3833/pdr.v2005.i59.682 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Arakis and Vectura Group entered into global development and commercialization agreement with Novartis for AD 237, a long-acting antimuscarinic agent for treating chronic obstructive pulmonary disease (COPD)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS